Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Older adults aged 70 and older who drive have higher crash death rates per mile driven compared to middle aged (35-54 years) adults who drive in the US. Prior studies have found that depression and or antidepressant medication use in older adults are associated with an increase in the vehicular crash rate. Using data from the prospective multi-site AAA Longitudinal Research on Aging Drivers Study, this analysis examined the independent and interdependent associations of self-reported depression and antidepressant use with driving behaviors that can increase motor vehicle crash risk such as hard braking, speeding, and night-time driving in adults over age 65. Of the 2951 participants, 6.4% reported having depression and 21.9% were on an antidepressant medication. Correcting for age, race, gender, and education level, participants on an antidepressant had increased hard braking events (1.22 [1.10-1.34]) but self-reported depression alone was not associated with changes in driving behaviors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370172 | PMC |
| http://dx.doi.org/10.1177/07334648241238313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Synthesis, and Biological Evaluation of 8-Phenyl-THIQ as Antidepressive Agents.
Drug Dev Res
September 2025
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, P. R. China.
The structural modification and derivatization of natural products represent an essential pathway for pharmaceutical innovation in the management of depression. The 8-phenyl tetrahydroisoquinoline, as a parent core, was obtained from magnoflorine by a structural simplification strategy. The present report details the synthesis and antidepressant activity studies of 8-phenyl-THIQ analogs.
View Article and Find Full Text PDFA Case Series of Young People Receiving Adjunctive Immunotherapy for Neuroimmune-Mediated Major Mood or Psychotic Syndromes.
Biol Psychiatry Glob Open Sci
November 2025
Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
Background: Neuroimmune processes are often implicated in young people with atypical neuropsychiatric disorders, yet treatment implications remain controversial. This case series details young people with primary psychiatric disorders who received adjunctive immunotherapy after thorough investigation and extensive conventional treatments.
Methods: We evaluated 45 individuals (93% female, ages 12-30 years) with atypical psychiatric presentations suggesting potential neuroimmune involvement.
Vortioxetine Improves Brain Glymphatic System Function, Functional Connectivity, and Cognitive Functions in Major Depressive Disorder.
Depress Anxiety
September 2025
Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou, China.
The therapeutic effects of vortioxetine on mood and cognition have been documented in major depressive disorder (MDD). This study aims to examine whether vortioxetine can improve brain glymphatic system function and connections among functional brain networks and to explore the underlying relationships among these changes. A total of 34 patients with MDD and 41 healthy controls (HCs) were recruited in the study.
View Article and Find Full Text PDFEvaluating the efficacy of psychotherapeutic and pharmacological treatments for depression on anhedonia: A systematic review and meta-analysis.
J Affect Disord
September 2025
CORE Data Lab, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK; Research Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK; iCope, Camden and Islington NHS Talking Therapies for anxiety and depress
Background: Anhedonia, the lack of interest or pleasure in activities, is a core but under-addressed symptom of depression. Consequently, little is known about the efficacy of treatments for alleviating anhedonia.
Objective: To evaluate the efficacy of psychotherapeutic and pharmacological treatments for depression at reducing symptoms of anhedonia.
Jiao-tai-wan and Its Bioactive Constituent Jatrorrhizine Exert Antidepressant Effects via the STING Pathway.
J Ethnopharmacol
September 2025
Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. Electronic address:
Ethnopharmacological Relevance: Jiao-tai-wan (JTW) is a classical traditional Chinese medicine formula that has long been used to treat insomnia. Recent pharmacological studies have highlighted its potential antidepressant effects. However, its role in regulating neuroinflammation associated with depression and the underlying mechanisms remains unclear.
View Article and Find Full Text PDF